We recognize many of our speakers and attendees are fighting COVID on the front lines. It is with great sadness that we must postpone our in-person conference in Denver in an effort to reduce further viral transmission. We will continue to offer our ACPE-accredited curriculum virtually in live-webinar format. We have already booked our 2021 conference at the Gaylord Rockies for August 12 -14, 2021 and hope you will join us as we continue to Define Cannabis Care.



AUGUST 13, 2020  

Course Details: Making Cannabis Medical

 In leiu of our live, accredited tours, we have asked selected speakers to prepare articles that detail the components that make Cannabis medical from plant to person.  These articles provide 3 hours of ACPE-approved credits. 

Examine the required components that make Cannabis medical

  1. Describe the process to maintain pharmaceutical-grade medicine
  2. Define potential contaminants during various stages of medical Cannabis production
  3. Determine the importance of genetic consistency or variability when creating pharmaceutical preparations
  4. Summarize the role of the 2018 Farm Bill and the implications for hemp–based products
  5. Outline testing standards that ensure consistent and reliable products
  6. Evaluate the importance of traceability across the manufacturing and dispensing process
  7. Explain the various analytical tools used to determine safety and potency
  8. Summarize operating procedures for safe handling of Cannabis products to prevent diversion
  9. Illustrate the need for HIPAA-compliant record keeping requirements in medical dispensaries
  10. Review product labeling to determine chemical composition, concentration, and calculate days supplied





Course Details: Clinical Cannabinoid Basics

845 AM – 10 AM CST: Endocannabinoids with Dr. Dustin Sulak, DO    

Discover the structure and function of the Endocannabinoid System (ECS)

  1. Identify the principle mediators of the ECS
  2. Examine the functions of the Endocannabinoid system (ECS)
  3. Explain the theory of Clinical Endocannabinoid Dysfunction (CECD)


10 AM – 1030 AM CST: Phytocannabinoid Formulations and Pharmacodynamics with Dr. Linda Klumpers, PhD

Analyze the commonly used formulations and pharmacodynamic properties of major cannabinoids

  1. Examine the varying THC and CBD plasma concentration onset and duration of commonly available formulations
  2. Summarize the pharmacodynamic effects of major and minor cannabinoids in humans
  3. Explore the role of the entourage hypothesis


1030 AM – 11 AM CST: Cannabinoid Metabolism and Drug-Drug Interactions with Dr. Linda Klumpers, PhD

Determine clinically relevant drug-drug and drug-disease interactions

  1. Summarize the CYP450 pathways for major cannabinoids
  2. Identify clinically relevant drug-drug and drug-disease interactions with THC and CBD
  3. Recommend strategies to manage drug-drug and drug-disease interactions with medical Cannabis products

11 AM – 1115 AM CST: Break  

1115 AM – 12 PM CST: Cannabis in Palliative Care with Dr. Michael Ruggiero, PharmD  

Evaluate the use of Cannabis medicine in palliative care

  1. Identify potential uses of Cannabis medicine
  2. Develop care plans for patients requiring palliative care using cannabinoid medicine for symptoms including: pain, nausea, vomiting, insomnia, spasms, and anxiety


12 PM – 1245 PM CST: Cannabis and Opioid Interactions with Dr. Dustin Sulak, DO      

Propose medical Cannabis as an alternative to opioids for pain management

  1. Discuss the overlap between the endogenous opioid and endocannabinoid systems
  2. Justify the use of cannabis products including THC and CBD in various pain models
  3. Examine dosing schedules that reduce opioid use to promote multimodal pain management


1245 PM – 145 PM CST: Lunch Break with Virtually Sponsored Product Theater 

Epidiolex (R) with Kendra Davies, PharmD from Greenwich Biosciences

145 PM – 215 PM CST:  Managing Cannabinoid Toxicity with Dr. Melani Kane, PharmD  

Review and resolve medication therapies for potential toxicity

  1. Define cannabinoid-specific and formulation-specific adverse reactions
  2. Outline potential strategies to mitigate cannabinoid medicine toxicity

215 PM – 3 PM CST: Incorporating Hemp/Cannabidiol in Your Clinical Practice with Dr. James Taylor, MD 

Interpret the clinical role of hemp-based Cannabidiol in clinical practice 

  1. Identify medical conditions that could benefit from hemp extractions 
  2. Compare the advantages and disadvantages to available CBD formulations including isolates, broad-spectrum, and full-spectrum extractions
  3. Formulate a monitoring plan to determine safe and effective use of CBD


3 PM – 315 PM CST: Break


315 PM – 345 PM CST: Patient Consultations; Osteopathic Perspective with Dr. Dustin Sulak, DO 

Integrate medical Cannabis as a complementary or alternative therapy

  1. Develop a care plan for presenting patients from an osteopathic perspective


345 – 3415 PM CST: Patient Consultations; Pharmacist Perspective with Dr. Shane Carmichael, PharmD

Integrate medical Cannabis as a complementary or alternative therapy

  1. Develop a care plan for presenting patients from a pharmacist perspective

    415 – 430 PM CST: Case Discussion – Complex Patient Presentations 

    Design safe and effective treatment regimens for complex patient presentations

    1. Formulate appropriate initial recommendations for cannabis-naïve and experienced patients
    2. Construct alternative recommendations for patients experiencing formulation-specific or cannabinoid-specific adverse reactions

    430 PM – 5 PM CST: Day 1 Q&A 

    • Dustin Sulak, Linda Klumpers, Michael Ruggiero, Melani Kane, Shane Carmichael, James Taylor

    >>> Conclusion of Day 1 Continuing Education accredited activities



    SATURDAY, AUGUST 15, 2020

    Course Details: Advanced Clinical Cannabinoid Considerations

    945 AM – 11 AM: Cannabis, Cognitive Functioning, and Mental Health with Dr. J Cobb Scott, PhD    

    Explain the neuropsychiatric implications of Cannabis use in various populations

    1. Identify the association of neurocognitive impairment in adolescent versus adult populations
    2. Compare functional MRI (fMRI) scans in recreational and medical Cannabis users and the implications to prevent harm
    3. Summarize the findings of the National Academy of Sciences, Engineering, and Medicine related to the development of Cannabis-induced anxiety, depression, schizophrenia, and bipolar mania.

    11 AM – 1145 AM CST: Cannabis in Neurological Disorders with Dr. Stacia Woodcock, PharmD

    Evaluate the role of phytocannabinoids in various degenerative and non-degenerative neurological disorders

    1. Summarize the literature surrounding medical cannabis in neurological disorders including; Multiple Sclerosis, Amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), Huntington’s disease (HD), and Alzheimer’s disease (AD)
    2. Demonstrate the benefit versus risk of phytocannabinoids in various neurological disorders
    3. Relate the pharmacologic actions of phytocannabinoids to conventional therapies in neurological disorders

    1145 AM – 12 PM CST: Cannabis in GI Disorders with Mr. Brian Essenter, RPh       

    Outline the role of cannabis medicine in gastrointestinal disorders

    1. Summarize the literature evaluating medical Cannabis in Crohn’s disease, ulcerative colitis, IBS, and liver disease
    2. Evaluate the use of common formulations in G/J tube

    12 PM – 1245 PM CST: Lunch Break featuring Presentations From our Virtual Sponsors:

    Elaine Richter, PharmD with MyCureAll
    Oludare Odumosu, PhD with Zelira Therapeutics

    1245 PM – 130 PM CST: Special Populations: Pregnancy and Lactation with Dr. Laura Borgelt, PharmD  

    Evaluate the use of medical Cannabis in special populations including pregnancy and lactation

    1. Explain the role of the ECS during prenatal and perinatal phases
    2. Interpret the risk of cannabis products for developing bodies
    3. Analyze the presence of cannabinoids in breast milk following maternal consumption


    130 PM – 215 PM CST: Special Populations: Pediatrics with Dr. Bonni Goldstein, MD  

    Evaluate the use of medical Cannabis in special populations including pediatrics and young adults  

    1. Identify potential pediatric conditions that could benefit from the use of medical Cannabis
    2. Compare the benefits and risks of phytocannabinoids; THC, CBD, CBG, CBN, and THCV in pediatric populations
    3. Construct initial dosing recommendations for pediatric patients with cancer, autism, pain, and epilepsy


    215 PM – 245 PM CST: Special Populations: Geriatrics with Dr. Dustin Sulak, DO

    Evaluate the use of medical Cannabis in special populations including geriatrics

    1. Summarize the risks of medical Cannabis in geriatric populations
    2. Develop dosing algorithms for cannabis-naïve elderly patients


    245 PM – 3 PM CST: Break


    3 PM – 345 PM CST: Cannabis in Exploratory Conditions with Dr. Kareem Abdalla, PharmD

    Identify the potential relationship between the ECS and various exploratory conditions 

    1. Illustrate the role of the ECS in conditions including psoriasis, solid organ transplant, bone marrow transplant, rheumatoid arthritis, and Tourette’s syndrome
    2. Demonstrate the potential interaction between Cannabis products and immunomodulators


    345 PM – 415 PM CST:  Panel: Future of Cannabis Pharmacy Moderated by Dr. Jeff Lombardo, PharmD, BCOP with Laszlo Mechtler, MD and Gene Morse, PharmD, BCPS

    Interpret the future of Cannabis medicine and the role of the healthcare professional 

    1. Explain the current legal landscape and regulatory challenges of Cannabis across the United States
    2. Evaluate the public perception and role of cannabinoids in medical models across the globe
    3. Identify challenges to standardization of medical products across state/country lines


    415 PM – 430 PM CST: Case Discussion: Special Populations

    Design safe and effective palliative care regimens for special populations including pediatrics and geriatrics  

    1. Formulate appropriate initial recommendations for sensitive populations including pediatrics and geriatrics
    2. Construct alternative recommendations for patients experiencing formulation-specific or cannabinoid-specific adverse reactions


    430 PM – 5 PM CST: Day 2 Q&A 

    • J Cobb Scott, Stacia Woodcock, Brian Essenter, Laura Borgelt, Bonni Goldstein, Dustin Sulak, Gene Morse, Jeff Lombardo, Laszlo Mechtler, and Kareem Abdalla

    >>> Conclusion of Day 2 Continuing Education accredited activities